UroGen Pharma (URGN) announced that adult patients living with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer now have improved access to an important therapy, as the ...
BCD Meetings & Incentives last week launched an EMEA-wide Pharmaceutical Code Compliance Team to reassure clients it operates within the strict requirements governing meetings staged by pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback